NM-2201
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
NM-2201 (also known as CBL-2201 and NA-5F-PIC ) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB 1 and CB 2 receptors with low nanomolar affinity.
NM-2201 (also known as CBL-2201 and NA-5F-PIC ) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB 1 and CB 2 receptors with low nanomolar affinity.
Pharmacology
NM-2201 acts as a full agonist with a binding affinity of 0.332 nM at CB 1 and 0.732 nM at CB 2 cannabinoid receptors. It has been linked to serious adverse events in users.
Legal status
NM-2201 is specifically banned in Sweden, Germany (Anlage II), and Japan but is also controlled in many other jurisdictions under analogue laws. On May 30, 2018 the United States Drug Enforcement Administration, Department of Justice published a notice of intent to place NM-2201 and 4 other synthetic cannabinoids in schedule I of the Controlled Substances Act. This notice went into effect on June 29, 2018.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329685635 under CC BY-SA 4.0; modifications have been made.